Sciencast Management LP Purchases Shares of 9,075 Humana Inc (HUM)

Sciencast Management LP purchased a new position in shares of Humana Inc (NYSE:HUM) in the 1st quarter, HoldingsChannel reports. The institutional investor purchased 9,075 shares of the insurance provider’s stock, valued at approximately $2,474,000. Humana makes up approximately 0.9% of Sciencast Management LP’s portfolio, making the stock its 12th biggest position.

Other institutional investors also recently made changes to their positions in the company. Moody National Bank Trust Division bought a new position in Humana in the 4th quarter valued at $30,000. We Are One Seven LLC bought a new position in Humana in the 4th quarter valued at $31,000. Proficio Capital Partners LLC grew its stake in Humana by 81.4% in the 4th quarter. Proficio Capital Partners LLC now owns 107 shares of the insurance provider’s stock valued at $31,000 after purchasing an additional 48 shares during the period. Exane Asset Management bought a new position in Humana in the 4th quarter valued at $43,000. Finally, Sontag Advisory LLC bought a new position in Humana in the 4th quarter valued at $47,000. Institutional investors and hedge funds own 94.52% of the company’s stock.

A number of research analysts have issued reports on HUM shares. Citigroup reduced their price objective on Humana from $397.00 to $362.00 and set a “buy” rating for the company in a research note on Thursday, February 7th. Zacks Investment Research upgraded Humana from a “hold” rating to a “buy” rating and set a $327.00 price objective for the company in a research note on Thursday, December 20th. Barclays restated a “buy” rating and issued a $351.00 price objective on shares of Humana in a research note on Sunday, January 6th. Cantor Fitzgerald restated a “hold” rating and issued a $325.00 price objective on shares of Humana in a research note on Wednesday, January 2nd. Finally, Cowen upgraded Humana from a “market perform” rating to an “outperform” rating and set a $275.02 price objective for the company in a research note on Friday, January 11th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and fourteen have assigned a buy rating to the stock. Humana presently has a consensus rating of “Buy” and a consensus target price of $355.06.

Shares of NYSE HUM traded down $0.31 during trading on Monday, reaching $253.00. 63,822 shares of the stock traded hands, compared to its average volume of 1,193,412. Humana Inc has a 52-week low of $251.69 and a 52-week high of $355.88. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.68 and a quick ratio of 1.68. The stock has a market capitalization of $34.36 billion, a PE ratio of 17.43, a P/E/G ratio of 1.07 and a beta of 0.93.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, February 6th. The insurance provider reported $2.65 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.12. Humana had a return on equity of 19.64% and a net margin of 2.96%. The firm had revenue of $14.17 billion for the quarter, compared to analysts’ expectations of $14.04 billion. During the same quarter in the prior year, the firm earned $2.06 EPS. The business’s revenue for the quarter was up 7.4% compared to the same quarter last year. As a group, equities analysts expect that Humana Inc will post 17.49 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Friday, March 29th will be given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date of this dividend is Thursday, March 28th. This is a boost from Humana’s previous quarterly dividend of $0.50. Humana’s dividend payout ratio is currently 3.44%.

In other news, insider Christopher H. Hunter sold 15,586 shares of the company’s stock in a transaction on Monday, February 25th. The stock was sold at an average price of $305.24, for a total transaction of $4,757,470.64. Following the transaction, the insider now owns 28,100 shares of the company’s stock, valued at approximately $8,577,244. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Roy A. Beveridge sold 8,278 shares of the company’s stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $307.16, for a total value of $2,542,670.48. Following the transaction, the insider now directly owns 12,409 shares in the company, valued at approximately $3,811,548.44. The disclosure for this sale can be found here. 0.54% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “Sciencast Management LP Purchases Shares of 9,075 Humana Inc (HUM)” was first published by WKRB News and is owned by of WKRB News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.wkrb13.com/2019/04/15/sciencast-management-lp-purchases-shares-of-9075-humana-inc-hum.html.

Humana Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Read More: Hedge Funds – Risk or Reward?

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.